Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Limited reports developments in immunology research and diagnostics, with a focus on immune response detection and post-acute infection syndromes. Company updates center on the in-development ViraxImmune T cell immune-profiling platform, PAIS-related conditions such as Long COVID, post-treatment Lyme disease and ME/CFS, and the ImmuneSelect research-use-only product portfolio.
Recurring news themes include clinical study activity, research collaborations, regulatory and quality-system preparation, commercial planning for immune-profiling products, private placements and other capital-structure actions. Updates also cover board composition, shareholder communications and Nasdaq listing-compliance matters for the company’s ordinary shares.
Virax Biolabs (NASDAQ: VRAX) has signed a non-exclusive distribution agreement with French company Tebubio to distribute its ImmuneSelect Research Use portfolio across the European Union, Norway, and Switzerland. The partnership aims to increase accessibility of ImmuneSelect for life science institutions throughout Europe.
Tebubio's established distribution networks and relationships across Europe will facilitate broader access to ImmuneSelect for research purposes. The collaboration represents a strategic expansion of Virax's immune profiling technology in the European market.
Virax Biolabs (NASDAQ: VRAX) has signed a distribution agreement with Europa Biosite to commercialize its ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through Cambridge Bioscience subsidiary. The partnership aims to expand Virax's commercial presence in these markets, making ImmuneSelect's immune profiling solutions accessible to researchers and pharmaceutical companies studying T cell response and immune status. Europa Biosite will provide local technical support and leverage its commercial infrastructure for product delivery.
Virax Biolabs Group (NASDAQ: VRAX) has extended its exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) to market Mpox Virus Real-Time PCR Detection Kits in Gulf Cooperation Council (GCC) countries. This expansion follows their existing agreement for Greece, Cyprus, and non-exclusive distribution in Europe. The CE-marked and MHRA-authorized kits boast a 96.7% sensitivity and 93.72% specificity, delivering results in under 70 minutes.
The agreement allows Cosmos to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Both companies express excitement about the partnership, with Virax CEO James Foster highlighting the expanded geographic reach and Cosmos CEO Greg Siokas noting the continued strong demand for Mpox virus detection kits.
Virax Biolabs (NASDAQ: VRAX), a biotechnology company specializing in viral disease detection and immune response diagnosis, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY. The company's Chief Operating Officer, Dr. Nigel McCracken, is presenting at the conference, which runs from September 9-11, 2024 at the Lotte New York Palace Hotel. A pre-recorded, on-demand presentation is now available for viewing.
Virax management is also offering one-on-one meetings during the conference for interested parties. The presentation can be accessed through the company's investor relations website.
Virax Biolabs Group (VRAX) has announced its participation in the 7th European Congress of Immunology (ECI) from September 1-4, 2024, in Dublin, Ireland. The company will showcase its immune profiling products for research use at Booth C13. Management will be available for discussions with research organizations and potential customers.
The ECI is a prestigious triennial event organized by the European Federation of Immunological Societies (EFIS), attracting over 3,000 delegates in the field of basic and clinical immunology. This year's congress theme is 'Conquering challenges with Immunology', highlighting the importance of immunological research in addressing current health challenges.
Virax Biolabs Group (NASDAQ: VRAX) has announced a distribution agreement for Mpox virus RT-PCR detection kits in 13 European countries and Gulf Cooperation Council (GCC) nations. The kits, which are CE-marked and authorized by the UK's MHRA, offer a sensitivity of 96.7% and specificity of 93.72%, delivering results in under 70 minutes.
CEO James Foster emphasized the company's commitment to providing healthcare professionals with tools to diagnose and mitigate Mpox spread. The agreement allows Virax to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in key European markets and GCC countries. Interested parties can contact Virax through their website for the Early Release Partnership Program (ERPP).
Virax Biolabs Group (Nasdaq: VRAX), a biotechnology company focused on viral disease detection, has closed a $5 million registered direct offering of ordinary shares. The company sold 1,108,892 ordinary shares at $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The gross proceeds of approximately $5 million will be used for working capital and general corporate purposes. The offering was conducted under a previously filed and effective shelf registration statement. A final prospectus supplement and accompanying base prospectus are available on the SEC's website.
Virax Biolabs Group (Nasdaq: VRAX), a biotechnology company focusing on immune response detection and viral disease diagnostics, announced a $5 million registered direct offering of 1,108,892 ordinary shares at $4.50 per share.
H.C. Wainwright & Co. is the exclusive placement agent. The offering is set to close around August 23, 2024, pending customary conditions.
Gross proceeds are estimated at $5 million, before placement fees and expenses. Net proceeds are intended for working capital and general corporate purposes.
The offering is conducted under a shelf registration statement (Form F-3, Registration No. 333-275893), previously filed with the SEC and declared effective on December 15, 2023. A final prospectus supplement and the base prospectus will be filed and made available on the SEC website.
Summary not available.
Summary not available.